A majority (89.1%) of ABVD patients received at least one supportive therapy to manage potential AEs induced by cHL treatment, including Granulocyte Colony Stimulating Factor (G‐CSF), Erythroid Stimulating Agent (ESA), blood transfusion, antibiotic/antiviral prophylaxis, and/or other treatments (anti‐emetic, anti‐diarrheal, analgesic, and/or dermatologic, Table 4). This evidence concerns the gene CSF3 and classic Hodgkin lymphoma.